---
title: "RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283660181.md"
description: "RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News"
datetime: "2026-04-22T04:01:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283660181.md)
  - [en](https://longbridge.com/en/news/283660181.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283660181.md)
---

# RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News

RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026 | CPIX Stock News

### Related Stocks

- [RDHL.US](https://longbridge.com/en/quote/RDHL.US.md)
- [CPIX.US](https://longbridge.com/en/quote/CPIX.US.md)

## Related News & Research

- [BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models](https://longbridge.com/en/news/286973840.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)
- [Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights | PPBT Stock News](https://longbridge.com/en/news/286556016.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Nanjing Leads Biolabs Wins Phase III Green Light for Key Cancer Drug Opamtistomig](https://longbridge.com/en/news/286828874.md)